Menu
Recruiting NCT06110403

Impact of Long-acting Bronchodilator- -Corticoid Inhaled Therapy on Ventilation, Lung Function and Breathlessness

Phase I / Phase II Interventional Copd

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: TRIXEO AEROSPHERE.
Who it may be relevant to
Registry conditions: Copd. Basic parameters: 40 years — 75 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Impact of Inhaled BGF 160 on Complexity and Variability of Tidal Breathing and Oscillatory Mechanics in Stable COPD Patient

Overview

Multicentre, prospective, non-randomised, single-arm, open label, mechanistic study to investigate the mechanism of action of BGF 160 on ventilation pattern complexity and variability

Interventions

  • Drug TRIXEO AEROSPHERE
    BGF 160 (Breztri Aerosphere™ in USA, Trixeo™ in France) Inhalation aerosol: pressurized metered dose inhaler containing a combination of budesonide (160 mcg), glycopyrrolate (9 mcg) and formoterol fumarate (4.8 mcg) as an inhalation aerosol. Oral inhalation: 2 inhalations of BGF 160 twice daily for 30 days.

Primary outcome measures

  • change in ventilation pattern complexity and variability [Time frame: between V2 baseline (pre-treatment) and V3 peak (2 hours (+/-30minutes) post dose at one month)]
Secondary outcome measures (9)
  • Change impulse oscillometry or forced oscillation: resistances at 5Hz, reactance at 5Hz [Time frame: between V2 base (pre-treatment) and V3 peak (2 hours (+/-30minutes) post dose]
  • Changes in FEV1 (spirometry) [Time frame: between V2 base (pre-treatment) and V3 peak (2 hours (+/-30minutes) post dose]
  • Change Plethysmographic Functional residual capacity (FRC) [Time frame: between V2 base (pre-treatment) and V3 peak (2 hours (+/-30minutes) post dose]
  • Changes measurement for noise limit, respiratory frequency, volume, largest Lyapounov component, resistances at 5Hz, reactance at 5Hz, FEV1and FRC versus TDI at V3 [Time frame: between V2 base measurement (pre-treatment) and V3 peak (2 hours (+/-30min)]
  • Baseline dyspnea index ( BDI) [Time frame: before administration of BGF 160 (at V2 base (pre-treatment)) and after administration (at V3 peak (2 hours (+/-30minutes) at one month)]
  • Transition dyspnea index (TDI) [Time frame: before administration of BGF 160 (at V2 base (pre-treatment)) and after administration (at V3 peak (2 hours (+/-30minutes) at one month)]
  • Modified dyspnea profile ( MDP) [Time frame: before administration of BGF 160 (at V2 base (pre-treatment)) and after administration (at V3 peak (2 hours (+/-30minutes) at one month)]
  • CAT score : COPD assessment test, [Time frame: before administration of BGF 160 (at V2 base (pre-treatment)) and after administration (at V3 peak (2 hours (+/-30minutes at one month)]
  • Likert scale for dyspnea and general health [Time frame: before administration of BGF 160 (at V2 base (pre-treatment)) and after administration (at V3 peak (2 hours (+/-30minutes) at one month)]

Eligibility criteria

Inclusion criteria

  • Provision of signed informed consent prior to any study specific procedure
  • Female or male subjects aged 40-75 years inclusive at the time of enrolment (Visit 1)
  • Documented history of COPD with a post-bronchodilator FEV1/FVC <0.70 and a post-bronchodilator 30 % < FEV1 <70% of predicted normal value (according to ERS 1993 reference values for spirometry ) at screening
  • Smoking history > 10 pack-years
  • Baseline significant dyspnea with a mMRC ≥ 2

Exclusion criteria

  • History or current diagnosis of asthma or ACOS (asthma-COPD overlap syndrome)
  • Respiratory infection or COPD exacerbation within 6 weeks (2 months if it resulted in hospitalization) prior to screening
  • Clinically significant or relevant cardiovascular conditions, laboratory tests, electrocardiogram (ECG) parameters:
  • Unstable angina/acute coronary syndrome, or Coronary Artery Bypass Grafting (CABG), Percutaneous Coronary Intervention (PCI) or myocardial infarction within the past 6 months.
  • Congestive heart failure New York Heart Association (NYHA) class III/IV.
  • Structural heart disease (hypertrophic cardiomyopathy, significant valvular disease).
  • Paroxysmal (within the past 6 months) or symptomatic chronic cardiac tachyarrhythmia.
  • Left bundle branch or high-degree AV block (second degree AV block type 2 and third degree AV block) unless the patient has a pacemaker.
  • Sinus node dysfunction with pauses.
  • Ventricular pre-excitation and/or Wolff-Parkinson-White syndrome.
  • QTcF interval >470 msec (QT interval corrected using Fridericia's formula; QTcF=QT/\[RR1/3\]).
  • Any other ECG abnormality deemed clinically significant by the Investigator.
  • Bradycardia with ventricular rate < 45 bpm.
  • Uncontrolled hypertension (> 165/95 mmHg).
  • Clinically relevant respiratory conditions (other than COPD)
  • Severe renal impairment eGFR < 30
  • Hepatic impairment
  • Narrow-angle glaucoma that, in the opinion of the Investigator, has not been adequately treated.
  • Symptomatic prostatic hypertrophy or bladder neck obstruction/urinary retention that is clinically significant
  • Patients not able to perform IOS, spirometry, plethysmography, or VT acquisition (10 min)
  • Any contraindication to LABA or LAMA drugs or to Inhaled corticosteroids
  • Pregnancy or breastfeeding
  • Woman of childbearing age without effective contraception
  • Any type of cancer within 5 years
  • Patients under guardianship
  • Refuse or incapacity to give an informed consent
  • Absence of social insurance

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

France · 1 center
  • CHU de Lille — Lille

Identifiers

NCT: NCT06110403 · 2022_0422 · 2022-003784-15

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗